IL309119A - Proteins that bind cd80 and/or cd86, and ox40l - Google Patents

Proteins that bind cd80 and/or cd86, and ox40l

Info

Publication number
IL309119A
IL309119A IL309119A IL30911923A IL309119A IL 309119 A IL309119 A IL 309119A IL 309119 A IL309119 A IL 309119A IL 30911923 A IL30911923 A IL 30911923A IL 309119 A IL309119 A IL 309119A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
chain variable
polypeptide
Prior art date
Application number
IL309119A
Other languages
English (en)
Hebrew (he)
Inventor
Alec Gross
Chia Chi Sun
Gang Chen
Yves Fomekong Nanfack
Qi An
Bijan Zakeri
Qingyong Ji
Original Assignee
Merck Patent Gmbh
Alec Gross
Chia Chi Sun
Gang Chen
Yves Fomekong Nanfack
Qi An
Bijan Zakeri
Qingyong Ji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Alec Gross, Chia Chi Sun, Gang Chen, Yves Fomekong Nanfack, Qi An, Bijan Zakeri, Qingyong Ji filed Critical Merck Patent Gmbh
Publication of IL309119A publication Critical patent/IL309119A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL309119A 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l IL309119A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208478P 2021-06-08 2021-06-08
US202263343268P 2022-05-18 2022-05-18
PCT/US2022/032482 WO2022261079A2 (en) 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l

Publications (1)

Publication Number Publication Date
IL309119A true IL309119A (en) 2024-02-01

Family

ID=84426420

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309119A IL309119A (en) 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l

Country Status (11)

Country Link
US (1) US20240262922A1 (cg-RX-API-DMAC10.html)
EP (1) EP4351644A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524880A (cg-RX-API-DMAC10.html)
KR (1) KR20240019224A (cg-RX-API-DMAC10.html)
AU (1) AU2022290257A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025553A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218785A1 (cg-RX-API-DMAC10.html)
IL (1) IL309119A (cg-RX-API-DMAC10.html)
MX (1) MX2023014695A (cg-RX-API-DMAC10.html)
TW (1) TW202315890A (cg-RX-API-DMAC10.html)
WO (1) WO2022261079A2 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2020192709A1 (en) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific polypeptide complexes

Also Published As

Publication number Publication date
KR20240019224A (ko) 2024-02-14
AU2022290257A1 (en) 2023-11-30
EP4351644A2 (en) 2024-04-17
WO2022261079A3 (en) 2023-01-19
MX2023014695A (es) 2024-01-15
CA3218785A1 (en) 2022-12-15
AU2022290257A9 (en) 2023-12-14
JP2024524880A (ja) 2024-07-09
BR112023025553A2 (pt) 2024-02-20
WO2022261079A2 (en) 2022-12-15
US20240262922A1 (en) 2024-08-08
TW202315890A (zh) 2023-04-16
EP4351644A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
IL280045A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
IL278090B1 (en) Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
IL316357A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US20230235004A1 (en) Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
JP2023520684A (ja) Ox40およびfapを標的化する二重特異性抗原結合分子
KR20200010354A (ko) 표적화된 면역관용
US20190241659A1 (en) Bispecific fusion polypeptides and methods of use thereof
JP2021508449A (ja) Ch3ドメイン中に挿入された特異的pd−l1結合配列
TW202124437A (zh) 以pd-1促效劑進行之標靶免疫耐受性
JP2025037987A (ja) 抗hla-g抗体及びその使用
JP2022533702A (ja) MAdCAM標的化免疫寛容
JP2021505156A (ja) 標的化免疫寛容
CN104379741B (zh) 抗人cd69抗体及其用于医疗目的的用途
US20210269496A1 (en) Tissue targeted immunotolerance with a cd39 effector
CN116348494A (zh) 双特异性分子和使用其的治疗方法
IL298867A (en) Bispecific immune cell engagers with binding specificity for hla-g and another antigen
IL302412A (en) Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
JP2022514187A (ja) IVIGの代替のための多量体ハイブリッドFc蛋白質
KR20220003567A (ko) Pd-1 및 lag-3에 대한 이중특이적 항체
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
WO2025054328A1 (en) Bispecific binding construct capable of binding to ackr4, compositions comprising a bispecific binding construct capable of binding to ackr4, and methods of using bispecific binding construct capable of binding to ackr4
US20240262922A1 (en) Proteins that bind cd80 and/or cd86, and ox40l
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
IL311275A (en) Materials that block and/or screen c. 28 is enough
HK40111520A (en) Proteins that bind cd80 and/or cd86, and ox40l